Insmed to present multiple abstracts from ERS Congress 2025

Insmed (INSM) announced that it will present seven abstracts from across its late-stage portfolio at the European Respiratory Society, ERS, 2025 Congress, taking place September 27 – October 1, 2025, in Amsterdam. Notably, data from the Phase 2 trial in treprostinil palmitil inhalation powder in patients with pulmonary arterial hypertension will be highlighted in the Congress’s Abstracts Leading to Evolution in Respiratory Medicine Trials session, which showcases important, late-breaking clinical data from all respiratory disease areas. In addition, presentations include three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating the efficacy and safety of brensocatib, including Japanese patient data, as well as Health Outcomes and Economic Research from The Health Improvement Network database in France and the United Kingdom in patients with non-cystic fibrosis bronchiectasis.